Addex Pharmaceuticals appoints ceo

Bharatt Chowrira has a strong track record in biopharmaceutical industry

Addex Pharmaceuticals, a Swiss biopharmaceutical company pioneering allosteric modulation-based drug discovery and development, has appointed of Bharatt Chowrira as chief executive. Chowrira has a strong track record in the biopharmaceutical industry with more than 17 years of experience, combining research, licensing, corporate development, operations and legal expertise.

Chowrira joins Addex after serving at Nektar Therapeutics, a US biopharmaceutical company developing therapeutics based on advanced polymer conjugate chemistry, as senior vice president and chief operating officer until January this year.

Prior to Nektar, he was executive director, Worldwide Licensing & External Research at Merck & Co. He has also served as vice president of Sirna Therapeutics, a wholly owned subsidiary of Merck, where his responsibilities included strategic planning and licensing.

Addex has also dissolved its transition committee, which was led by Addex vice-chairman Vincent Lawton and included André Mueller and Ray Hill, director. The transition committee was set up as an interim measure following the departure of the former ceo. In addition, Mueller has reverted to the position of non-executive chairman.

You may also like

Research & Development

Addex moves R&D operations to Campus Biotech in Geneva

To advance its portfolio of allosteric modulator drug candidates
Research & Development

Addex cuts staff from 19 to 2 people

CEO Bharatt Chowira and executive management step down
Research & Development

Addex to cut 28 jobs at Geneva operation

This is a strategic move from a position of strength, says ceo
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Masters of synthesis

Medicinal chemists take an initial lead compound and through systematic design work improve its potency, efficacy, and properties such as solubility and metabolism. The aim is to create a molecule that is effective, has few side-effects and can be scaled up, initially for clinical trials and subsequently for commercial manufacturing.
Research & Development

Addex makes job cuts to reduce costs

Restructures to focus on core r&d programmes and strategic partnerships
Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Subscribe now